

Survey: **DS2/26**
month: **May 2026**
Participant-No: **9907016**
valid from: **16.05.26**

Krajská nemocnice T. Bati, a.s.
Oddelení klinické biochemie
a farmakologie
Prim. MUDr. Tomáš Sálek, Ph.D., EuSpLM
Havlickovo nábreží 600
76275 ZLIN
CZECH REPUBLIC



Bonn, 6. July 2026

Certificate

This certificate is according to the current version of the RiliBÄK valid until the end of November 2026.

I. Screening (immunologic)

Correct findings were reported on the following:

- Amphetamine group
- Barbiturates
- Benzodiazepines
- Cannabinoids
- Cocain + metabolites
- Methadon + metabolites
- Opiates
- Tricycl. antidepressants
- Methamphetamin



Prof. Dr. C. Knabbe
EQA scheme director



Dr. Anja Kessler
Head of Reference Institute



Dr. Stefanie Gemein
EQAS-Board

This certificate is valid in conjunction with the final report dated 03.07.26.
This is available for download in the RfB-Online system.